Source comparison
Tesamorelin vs HIV Lipodystrophy: Clinical Response Comparison
Tesamorelin 2mg daily −15.2% (−1,084g trunk fat) −2.0 cm Minimal (+4.3 mg/dL fasting glucose, stable HbA1c) VAT rebounds ~40% within 12 weeks Most effective pharmacological option for visceral fat; requires ongoing therapy Diet + Exercise (structured) −3–7% (H
This comparison does not assign a generated winner or score.
- Tesamorelin 2mg daily
- −15.2% (−1,084g trunk fat)
- −2.0 cm
- Minimal (+4.3 mg/dL fasting glucose, stable HbA1c)
- VAT rebounds ~40% within 12 weeks
- Most effective pharmacological option for visceral fat; requires ongoing therapy
- Diet + Exercise (structured)
- −3–7% (HIV lipodystrophy cohorts)
- −0.5 to −1.2 cm
- No adverse effect
- Sustained if adherence maintained
- First-line but rarely sufficient alone in established lipodystrophy
- Exogenous GH (off-label)
- −10–12%
- −1.5 to −2.5 cm
- Significant (elevated fasting glucose, insulin resistance)
- VAT rebounds rapidly
- Higher metabolic risk; not FDA-approved for this indication
- Liposuction (surgical)
- N/A (removes tissue directly)
- Variable (−3 to −6 cm)
- None
- Permanent removal but no metabolic correction
- Addresses cosmetic concern but doesn't reverse metabolic dysfunction